PRECEPT – PRostatE CancEr Prognosis and Treatment

CHIEF INVESTIGATOR

A/Prof Niall Corcoran, Clinician Researcher, Department of Surgery, The University of Melbourne

COLLABORATING INSTITUTIONS	TYPE/ROLE
University of Melbourne	LEAD INSTITUTE
Walter and Eliza Hall Institute of Medical Research	COLLABORATOR
Cambridge University Hospital	COLLABORATOR
Cancer Sciences, University of Manchester	COLLABORATOR
Dana-Farber Cancer Institute	COLLABORATOR
Department of Medical Oncology, Monash Health	COLLABORATOR
Ontario Institute for Cancer Research	COLLABORATOR
School of Medicine, Faculty of Health at Deakin University	COLLABORATOR
School of Medicine, University of Sydney	COLLABORATOR
South Australian Health & Medical Research Insitute	COLLABORATOR
The Institute of Cancer Research	COLLABORATOR
South Australian Health & Medical Research Insitute	COLLABORATOR
Peter MacCallum Cancer Centre	COLLABORATOR
South West Warrnambool Hospital	COLLABORATOR
La Trobe University	COLLABORATOR

GRANT

3 year (2019-2022) $4m grant from the Prostate Cancer Research Alliance, an Australian Government and Movember Foundation Collaboration

SHARE ON SOCIAL MEDIA

This research program aims to:

1. Develop a tissue and blood test that will predict the future risk of progression in men with prostate cancer at the time of diagnosis.
2. Develop new ‘curative’ treatments in patients with high risk disease, starting with two clinical studies using novel agents to investigate if treatment effects can be improved.
3. Develop new tests for DNA markers that predict how tumours will respond to treatment and using those results to help individualise patient treatment according to their specific tumour type to maximise treatment effect.